These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Check the appropriate box:
|
||||
|
o
|
|
Preliminary Proxy Statement
|
||
|
o
|
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
||
|
x
|
|
Definitive Proxy Statement
|
||
|
o
|
|
Definitive Additional Materials
|
||
|
o
|
|
Soliciting Material Pursuant to §240.14a-12
|
||
|
|
|
|
|
|
|
LIFEVANTAGE CORPORATION
|
||||
|
(Name of Registrant as Specified In Its Charter)
|
||||
|
|
||||
|
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
|
||||
|
|
||||
|
Payment of Filing Fee (Check the appropriate box):
|
||||
|
x
|
|
No fee required.
|
||
|
¨
|
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
||
|
|
|
|
|
|
|
|
|
(1)
|
|
Title of each class of securities to which transaction applies:
|
|
|
|
(2)
|
|
Aggregate number of securities to which transaction applies:
|
|
|
|
(3)
|
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):
|
|
|
|
(4)
|
|
Proposed maximum aggregate value of transaction:
|
|
|
|
(5)
|
|
Total fee paid:
|
|
|
|
|||
|
¨
|
|
Fee paid previously with preliminary materials.
|
||
|
|
|
|||
|
¨
|
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
|
||
|
|
|
(1)
|
|
Amount Previously Paid:
|
|
|
|
(2)
|
|
Form, Schedule or Registration Statement No.:
|
|
|
|
(3)
|
|
Filing Party:
|
|
|
|
(4)
|
|
Date Filed:
|
|
1.
|
To elect six directors to hold office for a one-year term expiring at our fiscal year 2014 Annual Meeting of Shareholders or until their respective successors are elected and qualified;
|
|
2.
|
To ratify the appointment of EKS&H LLLP as our independent registered public accounting firm for our fiscal year ending June 30, 2014; and
|
|
3.
|
To conduct any other business properly brought before the meeting.
|
|
|
By Order of our Board of Directors
|
|
|
Sandy, Utah
|
/s/ Rob Cutler
|
|
|
September 27, 2013
|
Rob Cutler
|
|
|
|
General Counsel
|
|
|
|
Page
|
|
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
|
|
|
PROXY STATEMENT
|
|
|
|
|
|
General
|
|
|
Important Notice Regarding the Availability of Proxy Materials for the Fiscal 2014 Annual Meeting of Shareholders
|
|
|
Our Fiscal Year
|
|
|
Why am I receiving these materials?
|
|
|
Where and when is the annual meeting?
|
|
|
What am I voting on?
|
|
|
Who can vote at the annual meeting?
|
|
|
How do I vote?
|
|
|
How many votes do I have?
|
|
|
How are votes counted?
|
|
|
What are broker non-votes?
|
|
|
How many votes are needed to approve each proposal?
|
|
|
What does it mean if I receive more than one proxy card or Notice of Availability?
|
|
|
Can I change my vote after submitting my proxy?
|
|
|
What if I return a proxy card but do not make specific choices?
|
|
|
What is the quorum requirement?
|
|
|
Who is paying for this proxy solicitation?
|
|
|
When are shareholder proposals due for next year's annual meeting?
|
|
|
How can I find out the results of the voting at the annual meeting?
|
|
|
|
|
|
PROPOSAL 1 - ELECTION OF DIRECTORS
|
|
|
PROPOSAL 2 - RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
|
|
|
CORPORATE GOVERNANCE
|
|
|
EXECUTIVE OFFICERS
|
|
|
EXECUTIVE COMPENSATION
|
|
|
AUDIT RELATED MATTERS
|
|
|
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
|
|
|
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
|
|
|
CODE OF ETHICS
|
|
|
SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
|
|
|
HOUSEHOLDING OF PROXY MATERIALS
|
|
|
ANNUAL REPORT ON FORM 10-K
|
|
|
OTHER MATTERS
|
|
|
•
|
the election of six directors to our board of directors; and
|
|
•
|
the ratification of the selection of the appointment of EKS&H LLLP as our independent registered accounting firm for our fiscal year ending June 30, 2014.
|
|
•
|
Directors are elected by a plurality of the votes properly cast in person or by proxy. Cumulative voting is not permitted. The six nominees receiving the highest number of FOR votes will be elected. Broker non-votes are not
|
|
•
|
The ratification of the selection of EKS&H LLLP as our independent auditor for the fiscal year ending June 30, 2014 will be approved by our shareholders if the votes cast FOR the proposal exceed the votes cast AGAINST the proposal. A properly executed proxy marked “ABSTAIN” with respect to this proposal will not be voted and accordingly will have no effect on the outcome of this proposal. A broker or other nominee will generally have discretionary authority to vote on this proposal because it is considered a routine matter, and therefore we do not expect broker non-votes with respect to this proposal.
|
|
•
|
You may submit another properly completed proxy card with a later date;
|
|
•
|
You may send a written notice that you are revoking your proxy to our Corporate Secretary at LifeVantage Corporation, Attn: Corporate Secretary, 9815 S. Monroe Street, Suite 100, Sandy, Utah 84070; or
|
|
•
|
You may attend the annual meeting and vote in person. Simply attending the meeting will not, by itself, revoke your proxy.
|
|
Name
|
|
Age
|
|
Position with Company
|
|
Mr. Douglas C. Robinson
|
|
51
|
|
President, CEO and Director
|
|
Mr. Michael A. Beindorff
|
|
61
|
|
Director
|
|
Mr. David S. Manovich
|
|
61
|
|
Director
|
|
Mr. Garry Mauro
|
|
65
|
|
Director
|
|
Mr. George E. Metzger
|
|
66
|
|
Director
|
|
Mr. Richard Okumoto
|
|
61
|
|
Director
|
|
a.
|
assist board oversight of (i) the integrity of our financial statements, (ii) our compliance with legal and regulatory requirements, (iii) the qualifications and independence of our independent registered public accounting firm, and (iv) the performance of our internal audit function and independent registered public accounting firm;
|
|
b.
|
prepare an audit committee report as required by the SEC to be included in our annual proxy statement;
|
|
c.
|
evaluate the performance of and assesses the qualifications and independence of our independent registered public accounting firm;
|
|
d.
|
determine and approve the engagement of our independent registered public accounting firm;
|
|
e.
|
determine whether to retain or terminate our existing independent registered public accounting firm or to appoint and engage a new independent registered public accounting firm;
|
|
f.
|
review and approve the retention of our independent registered public accounting firm to perform any proposed permissible non-audit services;
|
|
g.
|
monitor the rotation of partners of our independent registered public accounting firm on the audit engagement team as required by law;
|
|
h.
|
confer with management and our independent registered public accounting firm regarding the effectiveness of internal controls over financial reporting;
|
|
i.
|
review and approve all related-party transactions;
|
|
j.
|
establish procedures, as required under applicable law, for the receipt, retention and treatment of complaints regarding accounting, internal accounting controls or auditing matters and the confidential and anonymous submission by employees of concerns regarding questionable accounting or auditing matters; and
|
|
k.
|
review our annual audited financial statements and quarterly financial statements with management and our independent registered public accounting firm, including reviewing disclosures under the section entitled “Management's Discussion and Analysis of Financial Condition and Results of Operations” contained in our periodic reports.
|
|
a.
|
identify and evaluate individuals qualified to serve as members of our board of directors (including individuals nominated by shareholders in proposals made in writing to our Secretary that are timely received and that contain sufficient background information concerning the nominee to enable proper judgment to be made as to the nominee's qualifications and are otherwise in compliance with applicable laws) and establish a process for recruiting suitable candidates to our board of directors, including identifying the characteristics and skills required by our board of directors and those existing on our board of directors;
|
|
b.
|
identify and recommend for our board of directors' selection nominees for election as directors at the meeting of shareholders at which directors are to be elected;
|
|
c.
|
recommend to our board of directors the appointment of directors to committees of our board of directors and, as appropriate, recommend rotation or removal of directors from such committees;
|
|
d.
|
cause to be prepared and recommend to our board of directors the adoption of corporate governance guidelines, and periodically review and assess the guidelines and recommend changes for approval by our board of directors;
|
|
e.
|
cause to be prepared and recommend to our board of directors the adoption of a code of ethics and a code of conduct, and from time to time review and assess the codes, and recommend changes for approval by our board of directors;
|
|
f.
|
provide minutes of meetings of the committee to our board of directors, and to report regularly to our board of directors with respect to significant actions and determinations made by the committee;
|
|
g.
|
at least annually, to review and reassess the charter of the committee and, if appropriate, recommend changes to our board of directors; and
|
|
h.
|
make recommendations to our board of directors regarding issues of management succession.
|
|
a.
|
assist our board of directors in developing and evaluating potential candidates for executive positions and to oversee the development of executive succession plans;
|
|
b.
|
review and approve on an annual basis the corporate goals and objectives with respect to compensation for our Chief Executive Officer. The committee evaluates at least once a year our Chief Executive Officer's performance in light of these established goals and objectives and based upon these evaluations recommends to the independent members of our board of directors our Chief Executive Officer's annual compensation, including base salary, annual and long-term incentive compensation. The Chief Executive Officer is not present during any meeting of the committee during which it will vote upon or deliberate the compensation of the Chief Executive Officer;
|
|
c.
|
review, approve and recommend to our board of directors on an annual basis the evaluation process and compensation structure for our other executive officers. The committee evaluates the performance of our executive officers and reviews, approves and recommends to our board of directors the annual compensation, including base salary, annual and long-term incentive compensation, for such executive officers, which is based on a proposal for such amounts submitted to the committee by our Chief Executive Officer;
|
|
d.
|
review and approve the initial compensation, including salary, and incentive compensation, for newly hired employees who are proposed to be executive officers of our company (other than a proposed newly hired Chief Executive Officer). The committee shall consider the proposals for compensation of such proposed newly hired executive officers submitted to the committee by our Chief Executive Officer. The committee may approve the compensation of newly hired employees who are proposed to be executive officers of our company (other than a proposed newly hired Chief Executive Officer) without further approval by our board of directors;
|
|
e.
|
provide oversight of management's decisions concerning the performance and compensation of our other officers, employees, consultants and advisors. The committee may delegate its authority on these matters with regard to non-officer employees and consultants to our officers and other appropriate supervisory personnel;
|
|
f.
|
review and approve on an annual basis management's recommendations for the salary range of non-officer employees by pay grade, percent merit increases and annual incentive pools;
|
|
g.
|
review our incentive compensation and other stock-based plans and recommend changes in such plans to our board of directors as needed. The committee has and exercises all the authority of our board of directors with respect to the administration of such plans;
|
|
h.
|
select, retain and terminate such compensation consultants, outside counsel and other advisors as it deems necessary or appropriate in its sole discretion. The committee may invite such consultants and advisors to attend its meetings or to meet with any members of the committee. The committee has sole authority to approve the fees and retention terms relating to such consultants and advisors;
|
|
i.
|
except with respect to the responsibilities set forth above regarding the compensation of our Chief Executive Officer, the committee may delegate its authority granted under its charter to a subcommittee of the committee (consisting either of a subset of members of the committee or, after giving due consideration to whether the eligibility criteria described above with respect to committee members and whether such other board of directors members satisfy such criteria, any members of our board of directors);
|
|
j.
|
review executive officer compensation for compliance with Section 16 of the Exchange Act and Section 162(m) of the Code, and other applicable laws, rules and regulations;
|
|
k.
|
review and approve non-routine employment agreements, severance arrangements and change in control agreements and provisions when, and if, appropriate, as well as any special supplemental benefits;
|
|
l.
|
review and recommend to our board of directors the compensation of independent directors, including annual and long-term incentive compensation; and
|
|
m.
|
perform any other activities consistent with its charter, our certificate of incorporation and by-laws, applicable NASDAQ Rules and any other applicable law, as the committee or our board of directors deems appropriate.
|
|
Name
|
|
Age
|
|
Position with Company
|
|
Mr. Douglas C. Robinson
|
|
51
|
|
President, Chief Executive Officer and Director
|
|
Mr. David W. Brown
|
|
50
|
|
President, LifeVantage Network
|
|
Mr. David Colbert
|
|
44
|
|
Chief Financial Officer and Treasurer
(1)
|
|
Mr. Robert Urban
|
|
54
|
|
Chief Operating Officer
|
|
Mr. Kirby L. Zenger
|
|
59
|
|
Chief Network Officer
|
|
Mr. David Toda
|
|
56
|
|
Chief Marketing Officer and General Manager of Asia Pacific
(2)
|
|
Mr. Robert H. Cutler
|
|
45
|
|
General Counsel and Corporate Secretary
|
|
Mr. Ryan Thompson
|
|
43
|
|
Senior Vice President of Global Sales
|
|
Mr. Eugene Tipps
|
|
39
|
|
Senior Vice President of Operations
|
|
Ms. Michelle Oborn
(3)
|
|
33
|
|
Vice President of Human Resources
|
|
(1)
|
Mr. Colbert was appointed Chief Financial Officer in August 2012.
|
|
(2)
|
Mr. Toda was appointed General Manager of Asia Pacific in October 2012 and Chief Marketing Officer in August 2013.
|
|
(3)
|
Ms. Oborn was appointed Vice President of Human Resources in July 2012.
|
|
NEO
|
|
Position
|
|
Douglas C. Robinson
|
|
President and Chief Executive Officer
|
|
David S. Colbert
(1)
|
|
Chief Financial Officer and Treasurer
|
|
Carrie E. McQueen
(2)
|
|
Former Chief Financial Officer and Treasurer
|
|
Robert M. Urban
|
|
Chief Operating Officer
|
|
Robert H. Cutler
|
|
General Counsel and Corporate Secretary
|
|
Ryan Thompson
|
|
Senior Vice President of Global Sales
|
|
Dr. Joe M. McCord
(3)
|
|
Former Chief Science Officer
|
|
(1)
|
Mr. Colbert became our Chief Financial Officer and Treasurer in August 2012.
|
|
(2)
|
Ms. McQueen served as our Chief Financial Officer and Treasurer until August 2012.
|
|
(3)
|
Dr. McCord resigned as our Chief Science Officer in October 2012, but continued to work for us as an employee until June 2013. In June 2013, Dr. McCord retired and we entered into a separation agreement with him.
|
|
•
|
Part I-Compensation Principles and Processes
. In this part we describe the important principles, processes and tools that help us determine compensation for our NEOs.
|
|
•
|
Part II-Compensation Components
. In this part we discuss the three material components of NEO compensation -base salary, annual and long-term incentive opportunities - and actual compensation paid or awarded to, or earned by, our NEOs in fiscal 2013.
|
|
•
|
Part III-Other Matters
. In this part we discuss other compensation practices that affect how we compensate our NEOs and actions taken regarding executive compensation after the end of fiscal 2013.
|
|
•
|
reward company and individual performance;
|
|
•
|
maintain an appropriate balance between base salary and annual and long-term incentive opportunities;
|
|
•
|
be externally competitive and internally equitable;
|
|
•
|
manage the distribution of gains between our NEOs and our shareholders; and
|
|
•
|
give us the flexibility to attract, retain and motivate talented executives.
|
|
Nutrisystem
|
Acorda Therapeutics
|
Auxilium Pharmaceuticals
|
|
Exelixis
|
ISTA Pharmaceuticals
|
AVEO Pharmaceuticals
|
|
Hi-Tech Pharmacal
|
The Medicines Company
|
Mannatech
|
|
Nutraceuticals Internationals
|
Schiff Nutrition International
|
Vitacost.com
|
|
Depomed
|
Obagi Medical Products
|
Spectrum Pharmaceuticals
|
|
•
|
Reward the NEOs for business and individual performance;
|
|
•
|
Encourage effective short-term performance while balancing long-term focus;
|
|
•
|
Provide a significant portion of total compensation opportunity that is at risk; and
|
|
•
|
Be externally competitive and internally equitable.
|
|
Revenue Target
|
|
EBITDA Target
|
|
Cash Incentive Potential of Messrs. Robinson, Colbert, Urban and Cutler as a % of Annual Base Salary
|
|
Cash Incentive Potential of Mr. Thompson as a % of Annual Base Salary
|
||
|
$262.5 million
|
|
$39.1 million
|
|
6
|
%
|
|
4.2
|
%
|
|
$290 million
|
|
$41.6 million
|
|
20
|
%
|
|
14
|
%
|
|
$350 million
|
|
$52.1 million
|
|
50
|
%
|
|
35
|
%
|
|
$410 million
|
|
$65.4 million
|
|
75
|
%
|
|
52.5
|
%
|
|
$425 million
|
|
$72 million
|
|
87.5
|
%
|
|
61.25
|
%
|
|
•
|
give NEOs a meaningful equity stake in our business;
|
|
•
|
encourage performance that increases long-term shareholder return;
|
|
•
|
align NEO's incentives directly with shareholder value; and
|
|
•
|
serve as a retention tool.
|
|
Shares Subject to Option
|
|
Exercise Price Per Share
|
|
Vesting Date
|
|
110,000
|
|
$0.75
|
|
March 15, 2011
|
|
500,000
|
|
$0.75
|
|
June 30, 2012
|
|
500,000
|
|
$1.20
|
|
June 30, 2013
|
|
500,000
|
|
$1.75
|
|
June 30, 2014
|
|
•
|
“cause” is generally defined as the occurrence of one or more of the following events:
|
|
◦
|
his conviction of, or a plea of guilty or nolo contendere to, a felony or other crime (except for misdemeanors which are not materially injurious to our business or reputation);
|
|
◦
|
his willful refusal to perform in any material respect the duties and responsibilities for our company or his failure to comply in any material respect with the terms of his employment agreement or of the proprietary information and inventions agreement he signed and delivered to us, or our policies and procedures, if such refusal or failure causes or is reasonably expected to cause injury to our company;
|
|
◦
|
his willful refusal to perform in any material respect the duties and responsibilities for our company or his failure to comply in any material respect with the terms of his employment agreement or of the proprietary information and inventions agreement he signed and delivered to us, or our policies and procedures, if such refusal or failure causes or is reasonably expected to cause injury to our company;
|
|
◦
|
fraud or other illegal conduct in the performance of his duties;
|
|
◦
|
his material breach of a material term of his employment agreement; or
|
|
◦
|
any conduct by him which is materially injurious to our company or materially injurious to our business reputation; and
|
|
•
|
“good reason” is generally defined as the occurrence of one or more of the following events without Mr. Robinson's consent:
|
|
◦
|
a material diminution in his responsibilities, duties or authority;
|
|
◦
|
a material diminution in his base salary; or
|
|
◦
|
our material breach of a material term of his employment agreement.
|
|
•
|
“cause” and “good reason” are generally defined in the same manner as described above for Mr. Robinson's employment agreement;
|
|
•
|
“disability” is generally defined to occur when Mr. Colbert is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for at least 12 continuous months;
|
|
•
|
a “change in control” is generally deemed to have occurred if:
|
|
◦
|
any person or group is or becomes the beneficial owner or directly or indirectly owner of our securities representing 60% or more of the combined voting power of our then outstanding securities;
|
|
◦
|
our shareholders approve a merger or consolidation of our Company with or into any other entity, other than a merger or consolidation which would result in our voting securities outstanding immediately prior thereto continuing to represent at least 60% of the combined voting power of the voting securities of our Company or the surviving entity outstanding immediately after such merger or consolidation; or
|
|
◦
|
our shareholders approve a plan of complete liquidation of our Company or an agreement for the sale or disposition of all or substantially all of our assets.
|
|
•
|
Mr. Thompson is eligible to participate in our annual incentive plan and, for fiscal year 2013, had the potential of receiving an incentive of up to 61.25% of his annual base salary.
|
|
•
|
For so long as Mr. Thompson remains employed with us as a key executive, he will be eligible to receive equity grants under our 2010 Long-Term Incentive Plan, or such other long term compensation plan as may then be in effect. Such equity grants, if any, will be made in the sole discretion of our board of directors and will be subject to the terms and conditions of the long term compensation plan under which the grants are made, the award agreement that must be exercised by Mr. Thompson as a condition to any grant, our insider trading policy, and any other terms and conditions that may be specified by our board of directors from time to time.
|
|
•
|
During Mr. Thompson's employment, he will be entitled to participate in all employee benefit plans and programs made available to other key executives. We will also pay all or a portion of the costs associated with the following employee benefit plans we sponsor: life insurance, long term disability, short term disability, health insurance, dental insurance and vision insurance.
|
|
Name and Principal Position
|
|
Year
|
|
Salary ($)
|
|
Bonus ($)(4)
|
|
Stock Awards ($)
(1)
|
|
Option Awards ($)
(1)
|
|
Non-equity Plan Compensation ($)
(2)
|
|
All Other Compensation ($)
|
|
Total ($)
|
|||||||
|
Douglas C. Robinson
,
|
|
2013
|
|
480,763
|
|
|
33,750
|
|
|
734,400
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,248,913
|
|
|
President and Chief
|
|
2012
|
|
443,529
|
|
|
135,000
|
|
|
—
|
|
|
—
|
|
|
286,331
|
|
|
—
|
|
|
864,860
|
|
|
Executive Officer
(3)
|
|
2011
|
|
100,042
|
|
|
101,250
|
|
|
—
|
|
|
1,205,195
|
|
|
—
|
|
|
—
|
|
|
1,406,487
|
|
|
David S. Colbert
, Chief
|
|
2013
|
|
273,067
|
|
|
—
|
|
|
577,140
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
850,207
|
|
|
Financial Officer
(5)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
Carrie E. McQueen
,
Former
|
|
2013
|
|
36,062
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
375,937(7)
|
|
|
411,999
|
|
|
Chief Financial Officer(6)
|
|
2012
|
|
240,562
|
|
|
—
|
|
|
—
|
|
|
189,654
|
|
|
106,485
|
|
|
—
|
|
|
625,209
|
|
|
Robert M. Urban
,
Chief
|
|
2013
|
|
346,042
|
|
|
—
|
|
|
587,520
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
933,562
|
|
|
Operating Officer
(8)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
Robert H. Cutler
,
|
|
2013
|
|
309,241
|
|
|
—
|
|
|
763,450
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,072,691
|
|
|
General Counsel
(9)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
Ryan Thompson
,
Senior
|
|
2013
|
|
210,021
|
|
|
—
|
|
|
434,125
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
644,146
|
|
|
Vice President of Global Sales
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
Dr. Joe McCord
,
Former
|
|
2013
|
|
116,385
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,731,518(11)(12)
|
|
|
1,847,903
|
|
|
Chief Science Officer
(10)
|
|
2012
|
|
120,000
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
69,750
|
|
|
878,911(11)
|
|
|
1,068,661
|
|
|
|
|
2011
|
|
—
|
|
|
—
|
|
|
—
|
|
|
82,584
|
|
|
—
|
|
|
447,410(11)
|
|
|
529,994
|
|
|
(1)
|
The amounts represent the total grant date fair value, as determined under Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 718, Stock Compensation, of all stock option awards or restricted stock awards, as applicable, granted to the applicable NEO under our 2010 LTIP during the applicable fiscal year. Assumptions used to calculate these amounts are included in Notes 2 and 5 to the financial statements included in our annual report on Form 10-K for the year ended June 30, 2013 filed with the SEC on September 12, 2013. These amounts reflect our accounting expense for these awards, and do not necessarily correspond to the actual value that may be realized by the NEOs.
|
|
(2)
|
The amounts reported in this column for fiscal years 2012 and 2011 are cash awards to our NEOs made pursuant to our Annual Incentive Plan. See the “
Compensation Discussion and Analysis
-
Annual Incentive Plan
” for information regarding these awards.
|
|
(3)
|
Mr. Robinson was hired as our President and CEO in March 2011. Mr. Robinson is also a member of our board of directors but does not receive additional compensation for his service in such capacity.
|
|
(4)
|
Mr. Robinson's employment agreement provided for the payment of the following transition bonuses which were paid based on his continuous employment through the applicable payment date: $101,250 on March 15, 2011; $67,500 on July 31, 2011; $33,750 on September 30, 2011; $33,750 on March 30, 2012; and $33,750 on October 1, 2012.
|
|
(5)
|
Mr. Colbert was hired as our CFO in August 2012.
|
|
(6)
|
Ms. McQueen resigned as our CFO in August 2012.
|
|
(7)
|
In August 2012, we entered into a separation agreement with Ms. McQueen that required us to pay the following amounts to Ms. McQueen: (i) an aggregate amount equal to her then annual base salary of $288,500 in twelve substantially equal monthly installments; (ii) $24,041 per month for her consulting services provided to us during the three month period after her termination; and (iii) $51,375, which is the product of (a) 37,500 multiplied by (b) $1.37, which is the difference between the closing price of a share of our common stock on the date of termination of her employment, or $2.94, and $1.57.
|
|
(8)
|
Mr. Urban was hired as our COO in May 2012.
|
|
(9)
|
Mr. Cutler was hired as our General Counsel in December 2011.
|
|
(10)
|
Dr. McCord resigned from his position as Chief Science Officer in October 2012, but continued to be employed with us until his retirement in June 2013.
|
|
(11)
|
Pursuant to his employment agreement, Dr. McCord was eligible to receive monthly compensation in an amount equal to $0.50 multiplied by the total net bottles sales of Protandim
®
(or substantially equivalent new products) during the preceding month.
|
|
(12)
|
In June 2013, we entered into a separation agreement with Dr. McCord which requires us to make 12 monthly payments to Dr. McCord in the aggregate amount of $1.7 million. The first such payment was made on June 27, 2013 in the amount of $141,667.
|
|
Name
|
Award Type
|
Grant Date
|
Estimated Future Payouts Under Non-Equity Incentive Plan Awards (1)
|
All Other Stock Awards: Number of Shares Underlying RSA (#)(2)
|
Grant Date Fair
Value of RSA ($)(3)
|
|||||||
|
Threshold ($)
|
Target ($)
|
Maximum ($)
|
||||||||||
|
Douglas C. Robinson
|
AIP
|
DNR(4)
|
28,626
|
|
238,550
|
|
417,463
|
|
|
|
||
|
|
RSA
|
6/24/2013
|
|
|
|
320,000
|
|
734,400
|
|
|||
|
David S. Colbert
|
AIP
|
DNR(4)
|
18,600
|
|
155,000
|
|
271,250
|
|
|
|
||
|
|
RSA
|
8/1/2012
|
|
|
|
82,000
|
|
255,840
|
|
|||
|
|
RSA
|
6/24/2013
|
|
|
|
140,000
|
|
321,300
|
|
|||
|
Robert M. Urban
|
AIP
|
DNR(4)
|
20,700
|
|
172,500
|
|
301,875
|
|
|
|
||
|
|
RSA
|
6/24/2013
|
|
|
|
256,000
|
|
587,520
|
|
|||
|
Robert H. Cutler
|
AIP
|
DNR(4)
|
20,106
|
|
167,550
|
|
293,213
|
|
|
|
||
|
|
RSA
|
1/25/2013
|
|
|
|
160,000
|
|
419,200
|
|
|||
|
|
RSA
|
6/24/2013
|
|
|
|
150,000
|
|
344,250
|
|
|||
|
Ryan Thompson
|
AIP
|
DNR(4)
|
9,484
|
|
79,030
|
|
138,302
|
|
|
|
||
|
|
RSA
|
1/25/2013
|
|
|
|
75,000
|
|
172,125
|
|
|||
|
|
RSA
|
6/24/2013
|
|
|
|
100,000
|
|
262,000
|
|
|||
|
(1)
|
The annual incentive plan is an annual incentive plan that pays a cash award for performance and is paid within four months of the end of the performance year. See our “
Compensation Discussion and Analysis-Part II-Compensation Components-Annual Incentive Plan
” for a detailed description of annual incentive plan awards. “Target” is the percentage of the NEO's base salary set prior to the beginning of the performance year. None of our NEOs actually received an award under our annual incentive plan for fiscal 2013.
|
|
(2)
|
Relates to awards of restricted stock under our 2010 LTIP. See our “
Compensation Discussion and Analysis-Part II-Compensation Components-Long-Term Incentive Plan
” above and also the Outstanding Equity Awards at Fiscal Year-End table below for a description of awards under our 2010 LTIP.
|
|
(3)
|
We calculate the grant date fair value of each award in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, Compensation-Stock Compensation (ASC Topic 718) and as described in Footnote 1 to the “Summary Compensation Table,” above.
|
|
(4)
|
None of our NEOs actually received an award under our annual incentive plan for fiscal 2013.
|
|
Name
|
Option Awards
|
|
Stock Awards
|
||||||||
|
Number of Securities Underlying Unexercised Options (#) Exercisable
|
Number of Securities Underlying Unexercised Options (#) Unexercisable
|
Option Exercise Price ($)
|
Option Expiration Date
|
|
Number of Shares of Restricted Stock That Have Not Vested (#)
|
Market Value of Shares of Restricted Stock that Have Not Vested ($)
|
|||||
|
Douglas C. Robinson
|
40,000
|
|
|
0.80
|
|
1/20/2021(1)
|
|
|
|
||
|
|
110,000
|
|
|
0.75
|
|
3/15/2021(2)
|
|
|
|
||
|
|
133,333
|
|
|
0.75
|
|
3/15/2021(3)
|
|
|
|
||
|
|
133,333
|
|
|
1.20
|
|
3/14/2021(4)
|
|
|
|
||
|
|
|
133,333
|
|
1.75
|
|
3/14/2021(5)
|
|
|
|
||
|
|
366,667
|
|
|
0.75
|
|
3/14/2021(6)
|
|
|
|
||
|
|
366,667
|
|
|
1.20
|
|
3/14/2021(7)
|
|
|
|
||
|
|
|
366,667
|
|
1.75
|
|
3/14/2021(8)
|
|
|
|
||
|
|
|
|
|
|
|
320,000(9)
|
734,400
|
|
|||
|
David S. Colbert
|
|
|
|
|
|
82,000(10)
|
190,240
|
|
|||
|
|
|
|
|
|
|
140,000(11)
|
324,800
|
|
|||
|
Robert M. Urban
|
40,625
|
|
109,375
|
|
3.19
|
|
5/29/2022(12)
|
|
|
|
|
|
|
|
|
|
|
|
10,875(13)
|
25,230
|
|
|||
|
|
|
|
|
|
|
256,000(14)
|
593,920
|
|
|||
|
Robert H. Cutler
|
53,125
|
|
96,875
|
|
2.87
|
|
3/14/2022(15)
|
|
|
|
|
|
|
|
|
|
|
|
57,622(16)
|
133,683
|
|
|||
|
|
|
|
|
|
|
160,000(17)
|
371,200
|
|
|||
|
|
|
|
|
|
|
150,000(18)
|
348,000
|
|
|||
|
Ryan Thompson
|
120,000
|
|
|
.70(19)
|
|
|
|
|
|
||
|
|
8,854
|
|
16,146
|
|
1.50(20)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
100,000(21)
|
232,000
|
|
|||
|
|
|
|
|
|
|
75,000(22)
|
174,000
|
|
|||
|
(1)
|
This option was granted on January 20, 2011 and originally was for 120,000 shares and was scheduled to vest in ten (10) equal monthly installments beginning on the date of grant. In connection with Mr. Robinson's employment as President and Chief Executive Officer in March 2011, Mr. Robinson agreed to forfeit 80,000 of the shares underlying this option.
|
|
(2)
|
This option was granted on March 15, 2011. The shares subject to this option were fully vested on grant.
|
|
(3)
|
This option was granted on March 15, 2011. The shares subject to this option fully vested on June 30, 2012.
|
|
(4)
|
This option was granted on March 15, 2011. The shares subject to this option fully vested on June 30, 2013.
|
|
(5)
|
This option was granted on March 15, 2011. The shares subject to this option will fully vest on June 30, 2014 assuming continuous employment with the Company.
|
|
(6)
|
This option was granted on March 15, 2011. The shares subject to this option fully vested on June 30, 2012.
|
|
(7)
|
This option was granted on March 15, 2011. The shares subject to this option fully vested on June 30, 2013.
|
|
(8)
|
This option was granted on March 15, 2011. The shares subject to this option will fully vest on June 30, 2014 assuming continuous employment with the Company.
|
|
(9)
|
These shares of restricted stock were granted on June 24, 2013 and vest in four equal annual installments beginning on June 24, 2014 assuming continuous employment with the Company.
|
|
(10)
|
These shares of restricted stock were granted on August 1, 2012 and vest in four equal annual installments beginning on August 1, 2013 assuming continuous employment with the Company.
|
|
(11)
|
These shares of restricted stock were granted on June 24, 2013 and vest in four equal annual installments beginning on June 24, 2014 assuming continuous employment with the Company.
|
|
(12)
|
This option was granted on May 29, 2012. One-fourth of the shares subject to this option vested on May 29, 2013, and the remaining shares vest in 36 equal monthly installments on the 29
th
day of each month assuming continuous employment with the Company.
|
|
(13)
|
These shares of restricted stock were granted on May 29, 2012 and vest in four equal annual installments beginning on May 29, 2013 assuming continuous employment with the Company.
|
|
(14)
|
These shares of restricted stock were granted on June 24, 2013 and vest in four equal annual installments beginning on June 24, 2014 assuming continuous employment with the Company.
|
|
(15)
|
This option was granted on March 15, 2012. One-fourth of the shares subject to this option vested on January 24, 2013, and the remaining shares vest in 36 equal monthly installments on the 24
th
day of each month assuming continuous employment with the Company.
|
|
(16)
|
These shares of restricted stock were granted on March 20, 2012 and vest in four equal annual installments beginning on January 24, 2013 assuming continuous employment with the Company.
|
|
(17)
|
These shares of restricted stock were granted on January 25, 2013 and vest in four equal annual installments beginning on January 25, 2014 assuming continuous employment with the Company.
|
|
(18)
|
These shares of restricted stock were granted on June 24, 2013 and vest in four equal annual installments beginning on June 24, 2014 assuming continuous employment with the Company.
|
|
(19)
|
This option was granted on March 29, 2009. The shares subject to this option fully vested on March 29, 2010 assuming continuous employment with the Company.
|
|
(20)
|
This option was granted on February 3, 2012. One-fourth of the shares subject to this option vested on January 25, 2013, and the remaining shares vest in 36 equally monthly installments on the 25
th
of each month assuming continuous employment with the Company.
|
|
(21)
|
These shares of restricted stock were granted on January 25, 2013 and vest in four equal annual installments beginning on January 25, 2014 assuming continuous employment with the Company.
|
|
(22)
|
These shares of restricted stock were granted on June 24, 2013 and vest in four equal annual installments beginning on June 24, 2014.
|
|
•
|
determine eligibility to receive awards;
|
|
•
|
determine the types and number of shares of stock subject to awards;
|
|
•
|
determine the price and terms of awards and the acceleration or waiver of any vesting;
|
|
•
|
determine performance goals or forfeiture restrictions and other terms and conditions; and
|
|
•
|
construe and interpret the terms of the plan, award agreements and other related documents.
|
|
•
|
stock options (which may be incentive or nonstatutory stock options);
|
|
•
|
restricted stock awards;
|
|
•
|
stock appreciation rights;
|
|
•
|
stock units; or
|
|
•
|
cash awards.
|
|
|
|
Option Awards
|
|
Stock Awards
|
||||||||
|
Name
|
|
Number of Shares Acquired on Exercise (#)
|
|
Value Realized on Exercise ($)(1)
|
|
Number of Shares Acquired on Vesting (#)
|
|
Value Realized on Vesting ($)(2)
|
||||
|
Douglas C. Robinson
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
David S. Colbert
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
Carrie E. McQueen
|
|
500,000
|
|
|
1,440,000
|
|
|
—
|
|
|
—
|
|
|
Robert M. Urban
|
|
—
|
|
|
—
|
|
|
3,625
|
|
|
8,519
|
|
|
Robert H. Cutler
|
|
—
|
|
|
—
|
|
|
19,207
|
|
|
51,283
|
|
|
Ryan Thompson
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
Dr. Joe M. McCord
|
|
740,408
|
|
|
1,347,110
|
|
|
—
|
|
|
—
|
|
|
(1)
|
Value realized upon exercise was determined by multiplying the number of stock options exercised by the difference between the fair market value of the underlying stock on the exercise date and the exercise price of the stock options.
|
|
(2)
|
Value realized upon vesting of stock awards was determined by multiplying the number of shares of restricted stock that vested by the fair market value of our common stock on the vesting date.
|
|
•
|
Executive's rate of base salary as of June 30, 2013;
|
|
•
|
Cash out of all stock options (whose vesting is accelerated) at their then intrinsic value as of June 30, 2013;
|
|
•
|
Cash severance as provided under the executive's employment agreement in effect as of June 30, 2013;
|
|
•
|
Change in control occurring on June 30, 2013;
|
|
•
|
Termination of executive's employment occurring on June 30, 2013;
|
|
•
|
A price per share of $2.32 which was the closing price of our common stock on June 28, 2013, the final trading day of fiscal 2013; and
|
|
•
|
The executives' employment agreements that were in effect as of June 30, 2013 were utilized.
|
|
|
|
Involuntary Termination ($)(1)
|
|
Involuntary Termination within 12 months after a change in control ($)(2)(3)
|
||
|
Douglas C. Robinson
|
|
|
|
|
||
|
Base salary continuation
|
|
477,100
|
|
|
—
|
|
|
Continuation of health insurance benefits
|
|
—
|
|
|
—
|
|
|
Acceleration of vesting of time-based stock options
|
|
—
|
|
|
—
|
|
|
Total
|
|
477,100
|
|
|
—
|
|
|
David S. Colbert
|
|
|
|
|
||
|
Base salary continuation
|
|
310,000
|
|
|
310,000
|
|
|
Continuation of health insurance benefits
|
|
—
|
|
|
—
|
|
|
Acceleration of vesting of time-based equity awards
|
|
—
|
|
|
515,040
|
|
|
Total
|
|
310,000
|
|
|
825,040
|
|
|
Robert M. Urban
|
|
|
|
|
||
|
Base salary continuation
|
|
345,000
|
|
|
345,000
|
|
|
Continuation of health insurance benefits
|
|
—
|
|
|
—
|
|
|
Acceleration of vesting of time-based equity awards
|
|
—
|
|
|
619,150
|
|
|
Total
|
|
345,000
|
|
|
964,150
|
|
|
Robert H. Cutler
|
|
|
|
|
||
|
Base salary continuation
|
|
335,100
|
|
|
335,100
|
|
|
Continuation of health insurance benefits
|
|
—
|
|
|
—
|
|
|
Acceleration of vesting of time-based equity awards
|
|
—
|
|
|
619,150
|
|
|
Total
|
|
335,100
|
|
|
954,250
|
|
|
Ryan Thompson
|
|
|
|
|
||
|
Base salary continuation
|
|
265,600
|
|
|
—
|
|
|
Continuation of health insurance benefits
|
|
—
|
|
|
—
|
|
|
Acceleration of vesting of time-based stock options
|
|
—
|
|
|
419,240
|
|
|
Total
|
|
265,600
|
|
|
419,240
|
|
|
Joe McCord
(4)
|
|
|
|
|
||
|
Base salary continuation
|
|
—
|
|
|
—
|
|
|
Bonus at Termination (5)
|
|
1,700,000
|
|
|
|
|
|
Continuation of health insurance benefits
|
|
—
|
|
|
—
|
|
|
Acceleration of vesting of time-based stock options
|
|
—
|
|
|
—
|
|
|
Total
|
|
1,700,000
|
|
|
—
|
|
|
Carrie E. McQueen
(6)
|
|
|
|
|
||
|
Base salary continuation
|
|
288,500
|
|
|
—
|
|
|
Bonus at Termination (7)
|
|
51,375
|
|
|
—
|
|
|
Continuation of health insurance benefits
|
|
—
|
|
|
—
|
|
|
Acceleration of vesting of time-based stock options
|
|
—
|
|
|
—
|
|
|
Total
|
|
339,875
|
|
|
—
|
|
|
(1)
|
For purposes of this table, an involuntary termination consists of, with respect to Messrs. Robinson, Colbert, Urban, Cutler and Thompson, our termination of their respective employment without cause or their resignation for good reason. See “
Compensation Discussion and Analysis-Part III-Other Matters-Employment Agreements.
”
|
|
(2)
|
For purposes of this table, an involuntary termination within 12 months after a change in control consists of, with respect to Messrs. Colbert, Urban and Cutler, the termination of their respective employment for any reason other than for cause, disability, death, presumed death or voluntary termination. See “
Compensation Discussion and Analysis-Part III-Other Matters-Employment Agreements
.”
|
|
(3)
|
Stock options are valued by subtracting the exercise price of such stock option from the closing price of shares of our common stock on June 28, 2013, the last trading day of fiscal 2013.
|
|
(4)
|
Dr. McCord retired on June 18, 2013. The actual post-employment payments paid, or to be paid, to Dr. McCord pursuant to our separation agreement with Dr. McCord are described above.
|
|
(5)
|
We entered into a separation agreement with Dr. McCord effective June 18, 2013, pursuant to which we agreed to pay Dr. McCord the aggregate amount of $1.7 million in twelve substantially equal monthly installments.
|
|
(6)
|
Ms. McQueen's employment terminated in August 2012. The actual post-employment payments paid, or to be paid, to Ms. McQueen pursuant to our separation agreement with Ms. McQueen are described above.
|
|
Name
|
|
Fees Earned or Paid in Cash($)
|
|
Stock Awards ($)(1)
|
|
All Other Compensation
|
|
Total($)
|
|||
|
Michael A. Beindorff
|
|
44,000
|
|
|
70,250
|
|
|
—
|
|
114,250
|
|
|
David S. Manovich
|
|
44,000
|
|
|
70,250
|
|
|
—
|
|
114,250
|
|
|
Garry Mauro
|
|
44,000
|
|
|
70,250
|
|
|
—
|
|
114,250
|
|
|
George E. Metzger
|
|
55,000
|
|
|
70,250
|
|
|
—
|
|
125,250
|
|
|
Richard Okumoto
|
|
40,000
|
|
|
140,500
|
|
|
—
|
|
180,500
|
|
|
Elwood H. Spedden
|
|
66,000
|
|
|
70,250
|
|
|
—
|
|
136,250
|
|
|
(1)
|
Following our fiscal 2013 annual meeting of shareholders held on November 14, 2012, we granted each continuing, non-employee director an award of 25,000 shares of restricted stock and the newly elected non-employee director (Mr. Okumoto) an award of 50,000 shares of restricted stock. Our closing share price on November 14, 2012 was $2.81. Subject to continued service on our board of directors, all awards of restricted stock awarded to a non-employee director will vest in full on the date of our fiscal 2014 Annual Meeting of Shareholders, which is scheduled to be held on November 13, 2013. The totals shown in this column represent the grant date fair value of each award of restricted stock in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, Compensation-Stock Compensation (ASC Topic 718) and as described in Footnote 1 to the “
Summary Compensation Table
,” above.
|
|
|
|
Option Awards
|
|
Stock Awards
|
||||||||
|
Name
|
|
Number of Securities Underlying Unexercised Options (#) Exercisable
|
|
Number of Securities Underlying Unexercised Options (#) Unexercisable
|
|
Option Exercise Price ($)
|
|
Number of Shares of Restricted Stock That Have Not Vested (#)
|
||||
|
Michael A. Beindorf
|
|
|
|
100,000
|
|
|
1.33
|
|
|
|
||
|
|
|
|
|
|
|
|
|
25,000
|
|
|||
|
David S. Manovich
|
|
|
|
100,000
|
|
|
1.33
|
|
|
|
||
|
|
|
|
|
|
|
|
|
25,000
|
|
|||
|
Garry Mauro
|
|
100,000
|
|
|
|
|
0.30
|
|
|
|
||
|
|
|
120,000
|
|
|
|
|
0.21
|
|
|
|
||
|
|
|
120,000
|
|
|
|
|
0.25
|
|
|
|
||
|
|
|
120,000
|
|
|
|
|
0.80
|
|
|
|
||
|
|
|
|
|
100,000
|
|
|
1.33
|
|
|
|
||
|
|
|
|
|
|
|
|
|
25,000
|
|
|||
|
George E. Metzger
|
|
|
|
100,000
|
|
|
1.33
|
|
|
|
||
|
|
|
|
|
|
|
|
|
25,000
|
|
|||
|
Richard Okumoto
|
|
|
|
|
|
|
|
50,000
|
|
|||
|
Elwood H. Spedden
|
|
|
|
100,000
|
|
|
1.33
|
|
|
|
||
|
|
|
|
|
|
|
|
|
25,000
|
|
|||
|
|
The Compensation Committee
|
|
|
|
|
|
|
|
George E. Metzger, Chair
|
|
|
|
Richard Okumoto
|
|
|
|
Elwood H. Spedden
|
|
|
The Audit Committee
|
|
Richard Okumoto, Chair
|
|
David S. Manovich
|
|
Garry Mauro
|
|
|
Fiscal year ended June 30,
|
||||||||
|
|
2,013
|
|
2,012
|
||||||
|
Audit Fees(1)
|
$
|
207,985
|
|
|
|
$
|
133,590
|
|
|
|
Audit-Related Fees
|
—
|
|
|
|
—
|
|
|
||
|
Tax Fees(2)
|
82,673
|
|
|
|
34,000
|
|
|
||
|
All Other Fees
|
—
|
|
|
|
—
|
|
|
||
|
|
$
|
290,658
|
|
|
|
$
|
167,590
|
|
|
|
Name of Beneficial Owner(1)
|
|
Number of Shares
|
|
Percent of Class
|
||
|
Michael A. Beindorff
|
|
270,700(2)
|
|
|
*
|
|
|
David S. Manovich
|
|
720,537(3)
|
|
|
*
|
|
|
Garry P. Mauro
|
|
849,954(4)
|
|
|
*
|
|
|
George Metzger
|
|
125,000(5)
|
|
|
*
|
|
|
Elwood Spedden
|
|
125,000(6)
|
|
|
*
|
|
|
Richard Okumoto
|
|
100,000(7)
|
|
|
*
|
|
|
Douglas C. Robinson
|
|
1,470,000(8)
|
|
|
1.24
|
%
|
|
David Colbert
|
|
216,227(9)
|
|
|
*
|
|
|
Robert Urban
|
|
323,860(10)
|
|
|
*
|
|
|
David Toda
|
|
50,000(11)
|
|
|
*
|
|
|
Rob Cutler
|
|
439,778(12)
|
|
|
*
|
|
|
Ryan Thompson
|
|
324,280(13)
|
|
|
*
|
|
|
Michelle Oborn
|
|
112,364(14)
|
|
|
*
|
|
|
Joe M. McCord
|
|
1,602,361(15)
|
|
|
*
|
|
|
Carrie E. McQueen
|
|
—
|
|
|
*
|
|
|
All executive officers and directors (18
persons)
|
|
8,924,993(16)
|
|
|
7.38
|
%
|
|
(1)
|
The shares of our common stock beneficially owned are reported on the basis of regulations of the SEC governing the determination of beneficial ownership of securities. Under the rules of the SEC, a person is deemed to be a “beneficial owner” of a security if that person has or shares voting power, which includes the power to vote or direct the voting of such security, or investment power, which includes the power to dispose of or to direct the disposition of such security. A person is also deemed to be a beneficial owner of any securities of which that person has a right to acquire beneficial ownership within 60 days. Securities that can be so acquired are deemed to be outstanding for purposes of computing such person's ownership percentage, but not for purposes of computing any other person's percentage. Under these rules, more than one person may be deemed beneficial owner of the same securities and a person may be deemed to be a beneficial owner of securities as to which such person has no economic interest. This table is based upon information supplied by officers, directors and principal shareholders and Schedules 13D and 13G filed with the SEC. Except as otherwise indicated in these footnotes and subject to community property laws where applicable, each of the beneficial owners has, to our knowledge, sole voting and investment power with respect to the indicated shares of common stock. In accordance with the beneficial ownership rules of the SEC, the table does not reflect an aggregate of 842,246 shares of common stock reserved for issuance upon the exercise of outstanding options not exercisable within 60 days held by certain of our directors and executive officers.
|
|
(2)
|
Includes 137,000 shares held directly by Mr. Beindorff, 8,000 shares owned by Mr. Beindorff's spouse which he is deemed to beneficially own, 700 shares owned by Mr. Beindorff's spouse in a custodial account for their minor children, which Mr. Beindorff is deemed to beneficially own and 25,000 shares directly owned by Mr. Beindorff pursuant to a Restricted Stock Award. Also includes the following shares which Mr. Beindorff has the right to acquire or will have the right to acquire within 60 days of September 13, 2013 upon the exercise of options: 100,000 shares at an exercise price of $1.33 per share.
|
|
(3)
|
Includes 305,537 shares owned in a joint trust account by Mr. Manovich and his spouse, 10,000 shares owned by Mr. Manovich, 40,000 shares held in Mr. Manovich's 401(k) plan, 240,000 shares owned by Mr. Manovich's spouse,
|
|
(4)
|
Includes 263,689 shares owned directly by Mr. Mauro, 1,265 shares owned by Mr. Mauro in a custodial account for his minor children, which he is deemed to beneficially own and 25,000 shares directly owned by Mr. Mauro pursuant to a Restricted Stock Award. Also includes the following shares which Mr. Mauro has the right to acquire or will have the right to acquire within 60 days of September 13, 2013 upon the exercise of options: 100,000 shares at an exercise price of $0.30 per share, 120,000 shares at an exercise price of $0.21 per share, 120,000 shares at an exercise price of $0.25 per share, 120,000 shares at an exercise price of $0.80 per share and 100,000 shares at an exercise price of $1.33 per share.
|
|
(5)
|
Includes 25,000 shares directly owned by Mr. Metzger pursuant to a Restricted Stock Award. Also includes the following shares which Mr. Metzger has the right to acquire or will have the right to acquire within 60 days of September 13, 2013 upon the exercise of options: 100,000 shares at an exercise price of $1.33 per share.
|
|
(6)
|
Includes 25,000 shares directly owned by Mr. Spedden pursuant to a Restricted Stock Award. Also includes the following shares which Mr. Spedden has the right to acquire or will have the right to acquire within 60 days of September 13, 2013 upon the exercise of options: 100,000 shares at an exercise price of $1.33 per share.
|
|
(7)
|
Consists of 50,000 shares directly owned by Mr. Okumoto and 50,000 shares pursuant to a Restricted Stock Award.
|
|
(8)
|
Includes 320,000 shares directly owned by Mr. Robinson pursuant to a Restricted Stock Award. Also includes the following shares which Mr. Robinson has the right to acquire or will have the right to acquire within 60 days of September 13, 2013 upon the exercise of options: 40,000 shares at an exercise price of $0.80 per share, 610,000 shares at an exercise price of $0.75 per share and 500,000 shares at an exercise price of $1.20 per share.
|
|
(9)
|
Consists of 216,227 shares directly owned by Mr. Colbert pursuant to Restricted Stock Awards.
|
|
(10)
|
Includes 1,600 shares directly owned by Mr. Urban and 269,135 shares owned by Mr. Urban pursuant to Restricted Stock Awards. Also includes the following shares which Mr. Urban has the right to acquire or will have the right to acquire within 60 days of September 13, 2013 upon the exercise of options: 53,125 shares at an exercise price of $3.19 per share.
|
|
(11)
|
Consists of 50,000 shares owned by Mr. Toda pursuant to Restricted Stock Awards.
|
|
(12)
|
Includes 374,153 shares directly owned by Mr. Cutler pursuant to Restricted Stock Awards. Also includes the following shares which Mr. Cutler has the right to acquire or will have the right to acquire within 60 days of September 13, 2013 upon the exercise of options: 65,625 shares at an exercise price of $2.87 per share.
|
|
(13)
|
Includes 6,343 shares directly owned by Mr. Thompson, 12,000 shares owned by Mr. Thompson's spouse which he is deemed to beneficially own, and 175,000 shares directly owned by Mr. Thompson pursuant to Restricted Stock Awards. Also includes the following shares which Mr. Thompson has the right to acquire or will have the right to acquire within 60 days of September 13, 2013 upon the exercise of options: 120,000 shares at an exercise price of $0.70 per share and 10,937 shares at an exercise price of $1.50 per share.
|
|
(14)
|
Includes 95,333 shares directly owned by Ms. Oborn pursuant to Restricted Stock Awards. Also includes the following shares which Ms. Oborn has the right to acquire or will have the right to acquire within 60 days of September 13, 2013 upon the exercise of options: 12,000 shares at an exercise price of $0.70 per share and 5,031 shares at an exercise price of $1.40 per share.
|
|
(15)
|
Consists of 1,455,800 shares directly owned by Dr. McCord and 146,561 shares owned by Dr. McCord pursuant to warrants.
|
|
(16)
|
Consists of 5,605,838 shares directly owned by our executive officers and directors as a group and 3,319,155 shares which our executive officers and directors as a group have the right to acquire or will have the right to acquire within 60 days of September 13, 2013.
|
|
|
By Order of the Board of Directors
|
|
|
September 27, 2013
|
/s/ Rob Cutler
|
|
|
|
Rob Cutler
|
|
|
|
General Counsel and Secretary
|
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|